HardEndocrinologyCardiovascular benefit of GLP-1 receptor agonistsau-amcau-racp
A 48-year-old woman with BMI 38 kg/m², hypertension and established coronary artery disease asks about new injectable weight loss medications she has heard might also reduce cardiovascular events. Which class of agents has evidence for reducing major adverse cardiovascular events in overweight patients with cardiovascular disease?